HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn ($0.01) per share for the quarter, up from their prior estimate of ($0.03). HC Wainwright currently has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.49 EPS, FY2027 earnings at $0.91 EPS and FY2028 earnings at $1.31 EPS.

Several other research firms also recently weighed in on BCRX. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, August 6th. JMP Securities upped their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 6th. Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.67.

BioCryst Pharmaceuticals Trading Down 0.8 %

BCRX traded down $0.06 during midday trading on Thursday, reaching $7.67. The company's stock had a trading volume of 2,336,619 shares, compared to its average volume of 2,159,022. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The stock's 50-day moving average is $7.78 and its 200-day moving average is $6.98. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -12.57 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analysts' expectations of $113.99 million. The business's quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.19) EPS.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 13.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 138,074 shares of the biotechnology company's stock valued at $701,000 after buying an additional 15,894 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter valued at $327,000. Inspire Investing LLC lifted its position in BioCryst Pharmaceuticals by 9.7% during the first quarter. Inspire Investing LLC now owns 69,466 shares of the biotechnology company's stock valued at $353,000 after purchasing an additional 6,141 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in BioCryst Pharmaceuticals by 200.8% during the first quarter. Russell Investments Group Ltd. now owns 58,725 shares of the biotechnology company's stock valued at $298,000 after purchasing an additional 39,205 shares during the period. Finally, ProShare Advisors LLC increased its holdings in BioCryst Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company's stock worth $246,000 after acquiring an additional 4,041 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.